Neldaleucel

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameNeldaleucel
Drug Alias NameMT601MT-601
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsMelanoma antigen preferentially expressed in tumors modulators +[8] 
TargetsMelanoma antigen preferentially expressed in tumorsCancer/testis antigen 1Baculoviral IAP repeat-containing protein 5 +[6] 
Therapy Area/IndicationsPancreatic NeoplasmsLymphoma, Non-HodgkinHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMarker Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCellipont BioservicesMarker Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsLymphoma, Non-HodgkinHodgkin Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A